Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18205
Country/Region: Kenya
Year: 2017
Main Partner: University of Maryland
Main Partner Program: University of Maryland Baltimore
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $7,083,122 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: TB/HIV (HVTB) $280,672
Testing: HIV Testing and Counseling (HVCT) $579,878
Sexual Prevention: Other Sexual Prevention (HVOP) $2,282,868
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $420,913
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $405,383
Treatment: Adult Treatment (HTXS) $3,021,348
Treatment: Pediatric Treatment (PDTX) $92,060
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2018 687
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2018 315
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2018 170
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2018 79
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2018 1,378
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2018 628
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2018 346
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2018 158
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2018 5,510
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2018 2,514
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2018 1,377
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2018 630
GEND_GBV 25-49, Female, Physical and/or Emotional Violence 2018 5,511
GEND_GBV 25-49, Female, Sexual Violence (Post-Rape Care) 2018 2,514
GEND_GBV 25-49, Male, Physical and/or Emotional Violence 2018 1,379
GEND_GBV 25-49, Male, Sexual Violence (Post-Rape Care) 2018 630
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2018 690
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2018 311
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2018 170
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2018 83
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 7,625
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 17,218
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 7,862
GEND_GBV Number of people receiving post-GBV care 2018 25,080
HTS_TST By Key Population: FSW, Negative 2018 20,237
HTS_TST By Key Population: MSM, Negative 2018 703
HTS_TST By Key Population: PWID, Negative 2018 2,995
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 247,272
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2018 34
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 2,812
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 10,485
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 13,642
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 803
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2018 182
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2018 284
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 101
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 84
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 34
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 18
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 47
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 119
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 5
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 5
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 18
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 60
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 97
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 263
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 438
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 1,382
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2018 88
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2018 147
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 1,389
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2018 311
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2018 478
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 11,519
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 5,802
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 41,274
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 12,507
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 78,364
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 38,129
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 2,360
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 2,807
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 3,720
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2018 37
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2018 5
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 29
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 33
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 52
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 65
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 162
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 225
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 28
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 24
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2018 478
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2018 227
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2018 254
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2018 438
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2018 242
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2018 1,395
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2018 685
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Female, Negative 2018 2,219
HTS_TST Service Delivery Point (Facility) VCT: 25-49, Male, Negative 2018 2,279
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2018 20
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2018 83
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 4
HTS_TST Sum of Test Result disaggregates 2018 8,480
HTS_TST_POS By Key Population: FSW, Positive 2018 701
HTS_TST_POS By Key Population: MSM, Positive 2018 161
HTS_TST_POS By Key Population: PWID, Positive 2018 213
HTS_TST_POS By Test Result: Positive 2018 8,480
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 65
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 402
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 1,167
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2018 29
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 19
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 56
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 55
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 9
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 44
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2018 24
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2018 17
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 234
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 24
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 925
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 239
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 3,072
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 1,435
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 118
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 164
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 10
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 48
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 49
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2018 33
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Female, Positive 2018 129
HTS_TST_POS Service Delivery Point (Facility) VCT: 25-49, Male, Positive 2018 55
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2018 10
KP_MAT Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months 2018 2,301
KP_MAT Sex: Female 2018 283
KP_MAT Sex: Male 2018 2,018
KP_MAT Sum of Sex disaggregates 2018 2,301
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 21,526
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 502
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 3,228
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 3,155
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 28,411
PMTCT_ART Already on ART at beginning of current pregnancy 2018 924
PMTCT_ART New on ART 2018 710
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 1,634
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 28,607
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 1,634
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 82
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 1,520
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 15
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 17
PMTCT_STAT By Age (Numerator): 10-14 2018 34
PMTCT_STAT By Age (Numerator): 15-19 2018 2,878
PMTCT_STAT By Age (Numerator): 20-24 2018 10,887
PMTCT_STAT By Age (Numerator): 25-49 2018 14,808
PMTCT_STAT By Number of known positives: 15-19 2018 25
PMTCT_STAT By Number of known positives: 20-24 2018 165
PMTCT_STAT By Number of known positives: 25-49 2018 786
PMTCT_STAT By Number of new negative: 10-14 2018 34
PMTCT_STAT By Number of new negative: 15-19 2018 2,812
PMTCT_STAT By Number of new negative: 20-24 2018 10,485
PMTCT_STAT By Number of new negative: 25-49 2018 13,642
PMTCT_STAT By Number of new positives: 15-19 2018 40
PMTCT_STAT By Number of new positives: 20-24 2018 237
PMTCT_STAT By Number of new positives: 25-49 2018 381
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 28,607
PMTCT_STAT_den By Age (Denominator): <15-19 2018 2,878
PMTCT_STAT_den By Age (Denominator): 10-14 2018 34
PMTCT_STAT_den By Age (Denominator): 20-24 2018 10,887
PMTCT_STAT_den By Age (Denominator): 25-49 2018 14,808
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 18
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 304
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 36
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 417
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 775
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 775
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 18
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 304
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 36
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 417
TB_PREV By Age/Sex (Numerator): <15, Female 2018 40
TB_PREV By Age/Sex (Numerator): <15, Male 2018 40
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 3,817
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 1,366
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 5,263
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 5,263
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 5,848
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 41
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 44
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 4,248
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 1,515
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 5,848
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 56
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 981
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 106
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1,354
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 2,497
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 2,541
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 56
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,002
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 110
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1,373
TX_CURR Age/Sex: <1 2018 56
TX_CURR Age/Sex: <1-9 2018 537
TX_CURR Age/Sex: 10-14 Female 2018 103
TX_CURR Age/Sex: 10-14 Male 2018 92
TX_CURR Age/Sex: 15-19 Female 2018 378
TX_CURR Age/Sex: 15-19 Male 2018 101
TX_CURR Age/Sex: 20-24 Female 2018 1,942
TX_CURR Age/Sex: 20-24 Male 2018 279
TX_CURR Age/Sex: 25-49 Female 2018 14,437
TX_CURR Age/Sex: 25-49 Male 2018 5,324
TX_CURR Age/Sex: 50+ Female 2018 1,378
TX_CURR Age/Sex: 50+ Male 2018 1,217
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 25,844
TX_CURR Sum of age/sex disaggregates 2018 479
TX_NEW Breastfeeding status 2018 4
TX_NEW By Age/Sex: <1 2018 18
TX_NEW By Age/Sex: 1-9 2018 41
TX_NEW By Age/Sex: 10-14 Female 2018 10
TX_NEW By Age/Sex: 10-14 Male 2018 16
TX_NEW By Age/Sex: 15-19 Female 2018 132
TX_NEW By Age/Sex: 15-19 Male 2018 48
TX_NEW By Age/Sex: 20-24 Female 2018 823
TX_NEW By Age/Sex: 20-24 Male 2018 140
TX_NEW By Age/Sex: 25-49 Female 2018 3,079
TX_NEW By Age/Sex: 25-49 Male 2018 1,269
TX_NEW By Age/Sex: 50+ Female 2018 188
TX_NEW By Age/Sex: 50+ Male 2018 84
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 5,848
TX_NEW Pregnancy status 2018 50
TX_NEW Sum of Age/Sex disaggregates 2018 5,789
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 25,788
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 23,035
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 277
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 19
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 269
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 22
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 15,063
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,186
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 5,744
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 455
TX_PVLS Numerator: Indication: Routine 2018 21,353
TX_PVLS Numerator: Indication: Targeted 2018 1,682
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 1,626
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Targeted 2018 85
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 86
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 5
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 345
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 25
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 338
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 26
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 16,815
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 1,321
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 6,415
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 503
TX_PVLS_den Denominator: Indication: Routine 2018 23,913
TX_PVLS_den Denominator: Indication: Targeted 2018 1,875
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 1,805
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Targeted 2018 95
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 95
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 5
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 37
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 44
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 4,188
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 1,494
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 5,763
TX_RET Numerator by Status: Breastfeeding 2018 4
TX_RET Numerator by Status: Pregnant 2018 50
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 5,848
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 41
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 44
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 4,247
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 1,516
TX_RET_den Denominator by Status: Breastfeeding 2018 4
TX_RET_den Denominator by Status: Pregnant 2018 50
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 25,844
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 310
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 63
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 63
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 132
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 52
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 401
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 389
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 18,136
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 6,918
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 4,139
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 257
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 772
TX_TB_den Denominator: By Screen Result: Negative 2018 20,676
TX_TB_den Denominator: By Screen Result: Positive 2018 5,168
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 5,168
Cross Cutting Budget Categories and Known Amounts Total: $157,500
Gender: Gender Based Violence (GBV) $17,500
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Human Resources for Health $140,000